'Time is costly': Modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa

AIDS

Volumn 22, Issue 1, 2008, Pages 107-113

  Ventelou, Bruno ^a,b,e   Moatti, Jean Paul ^a,c   Videau, Yann ^a   Kazatchkine, Michel ^d  

^a INSERM   (France)

^b Centre National de la Recherche Scientifique   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

Africa; AIDS impact; Antiretroviral treatment; Economic development; Endogenous growth model

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGOLA; ARTICLE; BENIN; CAMEROON; CENTRAL AFRICAN REPUBLIC; COTE D'IVOIRE; ECONOMIC ASPECT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCALE UP; ZIMBABWE;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; ECONOMICS; HEALTH POLICY; HIV; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL;

EID: 37349102339     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f1d49f     Document Type: Article

References (42)

1. UNAIDS. Resource needs for an expanded response to AIDS in low- and middle-income countries. Geneva: UNAIDS; August 2005.
2. Ainsworth M, Over M. AIDS and African development. World Bank - Research Observer 1994; 9: 203-240
3. Cuddington JT, Hancock J. The macroeconomic impact of AIDS in Malawi: a dualistic, labour surplus economy. J of African Eco 1995; 4:12-33.
4. Kambou G, Devarajan S, Over M. The economic impact of AIDS in an African country: simulations with a computable general equilibrium model of Cameroon. J of African Eco 1992; 1:109-130.
5. Lucas R. On the mechanics of economic development. J of Monetary Eco 1988; 22:3-42.
6. Azariadis C, Drazen A. Threshold externalities in economic development. Quart J of Eco 1990; 105:501-526.
7. Evans GW, Honkapohja S, Romer P. Growth cycles. Am Eco Rev 1998; 88:495-515.
8. Cooper R. Coordination games: complementarities and macroeconomics. New York: Cambridge University Press; 1999.
9. Haacker M. Modeling the macroeconomic impact of HIV/AIDS. IMF Working Paper 2002, 02/195.
10. Haacker M. The macroeconomics of HIV/AIDS. New York: IMF; 2004.
11. Bell C, Devarajan S, Gersbach H. Thinking about the long-run economic costs of AIDS. In: The macroeconomics of HIV/AIDS. Edited by Haacker M. New York: IMF; 2004. pp. 55-89.
12. McDonald S, Roberts J. AIDS and economic growth: A human capital approach. J of Dvt Eco 2006; 80:228-250.
13. Corrigan P, Glomm G, Mendez F. AIDS crisis and growth. J of Dvt Eco 2005; 77:107-124.
14. Grossman M. On the concept of health capital and the demand for health. J of Political Eco 1972; 80:1275-1294.
15. Strauss J, Thomas D. Health nutrition and economic development. J of Eco Lit 1998; 36:766-817.
16. World Health Organization (Sachs JD, ed.). Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health (CMH) of the World Health Organization. Geneva: World Health Organization; 2001.
17. Hansen Lars P, Heckman JJ. The empirical foundations of calibration. J of Eco Perspectives 1996; 10:87-104.
18. Cisse B. Etude de l'accès aux soins et l'utilisation des services de santé: une analyse comparative entre quatre capitales ouest-africaines. New York: UNICEF; 2003.
19. Cissé B, Luchini S, Moatti JP. Progressivity and horizontal equity in healthcare finance and delivery: What about Africa? Health Policy 2007; 80:51-68.
20. Arndt C, Lewis J. The macro implications of HIV/AIDS in South Africa: a preliminary assessment. S African J of Eco 2000; 68:856-887.
21. Bonnel R. HIV/AIDS: does it increase or decrease growth in Africa? S African J of Eco 2000; 68:820-855.
22. Couderc N, Ventelou B. AIDS, economic growth and epidemic trap in Africa. Oxford Development Studies 2005; 33:1-10.
23. Chakraborty S, Papageorgiou C, Perez-Sebastian F. Diseases and development, Department of Economics Working Paper Series, University of Oregon, 2005.
24. Acemoglu D, Johnson S, Robinson JA. The colonial origins of comparative development: an empirical investigation. Am Eco Rev 2001; 91:1369-1401.
25. Bloom D, Mahal A. Does the AIDS epidemic threaten economic growth?'. J of Econometrics 1997; 77:105-124.
26. Wehrwein P. The economic impact of AIDS in Africa. Harvard AIDS Review 2000; Winter issue: 12-14.
27. Sen A. Development as freedom. New York: Albert Knopf Inc; 1999.
28. Becker G, Philipson T, Soares R. The quantity and quality of life and the evolution of world inequality. Am Eco Rev 2005; 95:277-291.
29. Barnett T, Whiteside A. AIDS in the twenty-first century: disease and globalization. New-York: Palgrave Macmillan; 2002.
30. Moatti JP, N'Doye I, Hammer SM, Hale P, Kazatchkine M. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nat Med 2003; 9:1449-1452.
31. Salomon JA, Hogan DR, Stover J, Stanecki KA, Walker N, Ghys PD, Schwartländer B. Integrating HIV prevention and treatment: from slogans to impact. PLoS Medicine 2005; 2:16.
32. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294.
33. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, McFarland W. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-439.
34. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Medicine 2006; 3:124.
35. Mills S, Saidel T, Magnani R, Brown T. Surveillance and modelling of HIV, STI, and risk behaviours in concentrated HIV epidemics. Sex Transm Infect 2004; 80:ii57-ii62.
36. Crepaz N, Hart T, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292:224-236.
37. Diaz T, De Cock K, Brown T, Ghys PD, Boerma JT. New strategies for HIV surveillance in resource-constrained settings: an overview. AIDS 2005; 19:S1-S8.
38. De Cock KM, Bunnell R, Mermin J. Unfinished business-expanding HIV testing in developing countries. N Engl J Med 2006; 354:440-442.
39. Kevin M, De Cock K, Marum E, Mbori-Ngacha D. A serostatus-based approach to HIV/AIDS prevention and care in Africa. The Lancet 2003; 362:1847-1849.
40. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access. R&D and patents. Int J Healthcare Finance and Eco 2003; 3:183-205.
41. Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. The Lancet 2002; 360:1590-1595.
42. Stern and al. for the G8 Commission, 2005, Report, www. commissionforafrica.org.